GeroScience Study Identifies Progressive lncRNA Dysregulation in Progeria Arterial Phenotype

Researchers identified cell-type-specific, progressive dysregulation of cardiovascular-associated long non-coding RNAs in a mouse model of Hutchinson-Gilford Progeria Syndrome, highlighting novel targets for premature vascular aging.

A research team analyzed single-cell RNA sequencing data from aortic arch cells of wild-type and LmnaG609G/G609G mice at ages 6, 10, and 12 weeks.

The global analysis revealed 473 deregulated lncRNAs (403 upregulated, 70 downregulated) in vascular smooth muscle cells (VSMCs) and 174 deregulated lncRNAs (57 upregulated, 117 downregulated) in fibroblasts of progeric mice.

Several lncRNAs with established roles in cardiovascular biology, such as Carmn, Dancr, Gas5, Meg3, Neat1, Pvt1, and Trp53cor1, were dysregulated in VSMCs, with changes evolving dynamically as the disease progressed.

The most pronounced lncRNA dysregulation in VSMCs occurred in a disease-enriched subpopulation (VSMC II) characterized by high endoplasmic reticulum stress, phenotypic switching, and apoptotic signaling.

Progeria fibroblasts showed a distinct lncRNA expression profile (including H19, Gas5, Kcnq1ot1, and Pvt1) associated with fibrotic remodeling, proliferation, and inflammation.

Transcription factor motif enrichment analysis predicted that promoters of dysregulated lncRNAs are bound by transcription factors linked to cellular stress responses, unfolded protein response, TGF-ß signaling, and phenotypic switching.

Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare premature aging disorder characterized by severe systemic symptoms, where cardiovascular events driven by vascular smooth muscle cell loss and arterial stiffening are the main cause of death.

Current therapeutic options for HGPS remain limited; the farnesyltransferase inhibitor lonafarnib extends life expectancy but does not fully halt severe cardiovascular decline and causes gastrointestinal side effects.

The identification of specific, dynamically altered lncRNAs provides a temporal and spatial catalog of non-coding RNA candidates that may regulate vascular smooth muscle cell and fibroblast dysfunction during disease progression.

The study shows that the dysregulation is highly cell-type specific, meaning therapeutic interventions targeting lncRNAs in HGPS will likely require cell-selective or tissue-targeted delivery mechanisms.

The identification of conserved, early-dysregulated lncRNAs (such as Neat1, Dancr, Meg3, and Trp53cor1) provides specific candidate sequences for biotechnology platforms developing RNA-targeting therapeutics, including antisense oligonucleotides, siRNA, and CRISPR-based transcriptional modulators.

The validation of lncRNAs as key modulators of phenotypic switching in vascular smooth muscle cells supports a shift in cardiovascular drug discovery towards targeting regulatory non-coding RNAs rather than traditional protein-coding genes.

The dynamic, age-dependent changes mapped in this study demonstrate the utility of single-cell transcriptomics to establish preclinical baseline signatures, potentially refining target selection and screening processes for rare laminopathies and broader age-related vascular stiffness.

Preclinical validation studies evaluating whether in vivo knockdown or overexpression of prioritized lncRNAs (e.g., using LNA GapmeRs or viral vectors) can prevent vascular smooth muscle cell loss and fibrotic remodeling in HGPS models.

Further research into the therapeutic potential of Neat1, particularly regarding its structural role in paraspeckle formation and its connection to progerin-induced nuclear envelope stress.